Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Core Biogenesis |
| Country | France |
| Start Date | Jan 01, 2023 |
| End Date | Dec 31, 2024 |
| Duration | 730 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 190139157 |
Core Biogenesis uses plant-based expression systems for the very large-scale and high-quality bioproduction of pharmaceutical-grade recombinant proteins.
The latter are used as growth factors (GF) in synthetic cell culture media for clinical and commercial scale biomanufacturing of cell therapy.
The company has developed a novel advanced proprietary bioprocess integrating breakthrough innovations overcoming major technical issues of plant systems by offering a 25-fold yield increase and a 10-fold cost reduction.
Its biomanufacturing platform will enable Core Biogenesis to fully exploit the great potential of plants for large and scalable production capacity as plants are well known to be the most promising system for production upscaling. Core Biogenesiss ambition is to position itself as the European leader in plant-based biomanufacturing by 2025.
Core Biogenesis
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant